MEREO BIOPHARMA GROUP PLC Accrued Liabilities, Current
MEREO BIOPHARMA GROUP PLC (MREO) had Accrued Liabilities, Current of $2.46 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-11
- 2026-06-30: Accrued Liabilities, Current $2.46M.
- 2026-03-31: Accrued Liabilities, Current $2.05M.
- 2025-12-31: Accrued Liabilities, Current $2.03M.
- 2025-09-30: Accrued Liabilities, Current $4.12M.
| Period end | Accrued Liabilities, Current |
|---|---|
| 2026-06-30 | $2.46M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $2.05M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $2.03M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $4.12M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $5.04M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $2.93M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $4.07M 10-K · filed 2026-03-19 |
| 2024-09-30 | $3.53M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $3.72M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $2.54M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $5.47M 10-K · filed 2025-03-26 |
| 2022-12-31 | $5.44M 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |